Panagora Asset Management’s UroGen Pharma URGN Stock Holding History

Panagora Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Sell	74,024 -24,031	-25%	-$651K	0.01%	561
2026 Q1	$1.76M	Buy	98,055 +24,000	+32%	+$481K	0.01%	610
2025 Q4	$1.73M	Sell	74,055 -110,327	-60%	-$2.39M	0.01%	605
2025 Q3	$3.68M	Sell	184,382 -77,403	-30%	-$1.39M	0.01%	407
2025 Q2	$3.59M	Buy	261,785 +168,908	+182%	+$1.62M	0.02%	370
2025 Q1	$1.03M	Buy	+92,877	New	+$990K	0.01%	653

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Panagora Asset Management's URGN Position: Q2 2026 in Review

Panagora Asset Management reduced its UroGen Pharma (URGN) stake by 25% in Q2 2026, selling an estimated $651K and leaving 74,024 shares worth $2.72M. The position accounts for 0.01% of the portfolio, ranked #561.

Panagora Asset Management first reported a position in URGN in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.68M in Q3 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

Panagora Asset Management held 74,024 shares of UroGen Pharma worth $2.72M as of Q2 2026.
Panagora Asset Management sold 24,031 UroGen Pharma shares in Q2 2026, an estimated $651K.
UroGen Pharma made up 0.01% of Panagora Asset Management's portfolio in Q2 2026, its #561 holding.
Panagora Asset Management first reported a position in UroGen Pharma in Q1 2025 and has held it in 6 quarters since.
Panagora Asset Management's UroGen Pharma position peaked at $3.68M in Q3 2025.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.